Levomilnacipran

Levomilnacipran
Molecular structure of levomilnacipran
3D representation of levomilnacipran
Clinical data
Trade namesFetzima
AHFS/Drugs.comMonograph
MedlinePlusa613048
License data
Routes of
administration
By mouth
Drug classSerotonin–norepinephrine reuptake inhibitor (SNRI)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability92%
Protein binding22%
MetabolismLiver (primarily by CYP3A4)
Elimination half-life12 hours
ExcretionKidney
Identifiers
  • (1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H22N2O
Molar mass246.354 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2
  • InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1 X markN
  • Key:GJJFMKBJSRMPLA-DZGCQCFKSA-N X markN
 X markNcheckY (what is this?)  (verify)

Levomilnacipran, sold under the brand name Fetzima, is an antidepressant medication used for the treatment of major depressive disorder in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor.

Levomilnacipran was approved for medical use in the United States in July 2013.